Literature DB >> 24900223

Structure-Activity Studies on Antiproliferative Factor (APF) Glycooctapeptide Derivatives.

Piotr Kaczmarek1, Gillian M Tocci2, Susan K Keay3, Kristie M Adams1, Chen-Ou Zhang4, Kristopher R Koch5, David Grkovic5, Li Guo5, Christopher J Michejda2, Joseph J Barchi1.   

Abstract

Antiproliferative factor (APF), a sialylated glycopeptide secreted by explanted bladder epithelial cells from interstitial cystitis/painful bladder syndrome (IC/PBS) patients, and its unsialylated analogue (as-APF) significantly decrease proliferation of bladder epithelial cells and/or certain carcinoma cell lines in vitro. We recently reported a structure-activity relationship profile for the peptide portion of as-APF and revealed that truncation of the C-terminal alanine did not significantly affect antiproliferative activity. To better understand the structural basis for the maintenance of activity of this truncated eight amino acid as-APF (as-APF8), we synthesized several amino acid-substituted derivatives and studied their ability to inhibit bladder epithelial cell proliferation in vitro as well as their solution conformations by CD and NMR spectroscopy. While single amino acid changes to as-APF8 often strongly reduced activity, full potency was retained when the trivaline tail was replaced with three alanines. The Ala(6-8) derivative 9 is the simplest, fully potent APF analogue synthesized to date.

Entities:  

Keywords:  Interstitial cystitis/painful bladder syndrome; antiproliferative; glycopeptide; hydrophobicity; peptide conformation

Year:  2010        PMID: 24900223      PMCID: PMC4007904          DOI: 10.1021/ml100087a

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

1.  Interstitial cystitis: a chronic disease with ever-increasing recognition and prevalence.

Authors:  C Lowell Parsons
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

2.  Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987.

Authors:  J Y Gillenwater; A J Wein
Journal:  J Urol       Date:  1988-07       Impact factor: 7.450

Review 3.  The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components.

Authors:  Dieter Seebach; Albert K Beck; Daniel J Bierbaum
Journal:  Chem Biodivers       Date:  2004-08       Impact factor: 2.408

4.  Interstitial cystitis is associated with intraurothelial Tamm-Horsfall protein.

Authors:  J E Fowler; W L Lynes; J L Lau; L Ghosh; A Mounzer
Journal:  J Urol       Date:  1988-12       Impact factor: 7.450

5.  Chronic ulcerating interstitial cystitis (Hunner's ulcer). A study of 28 cases.

Authors:  B H Smith; L P Dehner
Journal:  Arch Pathol       Date:  1972-01

6.  Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis).

Authors:  C L Parsons; J D Lilly; P Stein
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

7.  Structure-activity relationship studies for the peptide portion of the bladder epithelial cell antiproliferative factor from interstitial cystitis patients.

Authors:  Piotr Kaczmarek; Susan K Keay; Gillian M Tocci; Kristopher R Koch; Chen-Ou Zhang; Joseph J Barchi; David Grkovic; Li Guo; Christopher J Michejda
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

8.  An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide.

Authors:  Susan K Keay; Zoltan Szekely; Thomas P Conrads; Timothy D Veenstra; Joseph J Barchi; Chen-Ou Zhang; Kristopher R Koch; Christopher J Michejda
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-28       Impact factor: 11.205

9.  Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis.

Authors:  Gennady Slobodov; Michael Feloney; Christopher Gran; Kimberly D Kyker; Robert E Hurst; Daniel J Culkin
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

10.  Differentiation potential of urothelium from patients with benign bladder dysfunction.

Authors:  Jennifer Southgate; Claire L Varley; Mary A E Garthwaite; Jennifer Hinley; Fiona Marsh; Jens Stahlschmidt; Ludwik K Trejdosiewicz; Ian Eardley
Journal:  BJU Int       Date:  2007-06       Impact factor: 5.588

View more
  5 in total

1.  Conformational determinants of the activity of antiproliferative factor glycopeptide.

Authors:  Sairam S Mallajosyula; Kristie M Adams; Joseph J Barchi; Alexander D MacKerell
Journal:  J Chem Inf Model       Date:  2013-05-15       Impact factor: 4.956

2.  Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome.

Authors:  Md Shadman Ridwan Abid; Haowen Qiu; Bridget A Tripp; Aline de Lima Leite; Heidi E Roth; Jiri Adamec; Robert Powers; James W Checco
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

3.  Chemical synthesis of a heparan sulfate glycopeptide: syndecan-1.

Authors:  Bo Yang; Keisuke Yoshida; Zhaojun Yin; Hang Dai; Herbert Kavunja; Mohammad H El-Dakdouki; Suttipun Sungsuwan; Steven B Dulaney; Xuefei Huang
Journal:  Angew Chem Int Ed Engl       Date:  2012-09-07       Impact factor: 15.336

4.  Antiproliferative factor (APF) binds specifically to sites within the cytoskeleton-associated protein 4 (CKAP4) extracellular domain.

Authors:  Burzin Chavda; Jun Ling; Thomas Majernick; Sonia Lobo Planey
Journal:  BMC Biochem       Date:  2017-09-11       Impact factor: 4.059

5.  Glycoamino Acid Analogues of the Thomsen-Friedenreich Tumor-Associated Carbohydrate Antigen: Synthesis and Evaluation of Novel Antiproliferative Factor Glycopeptides.

Authors:  Maqbool A Siddiqui; Shailesh Ambre; Susan K Keay; Jeffrey M Rhyne; Chen-Ou Zhang; Joseph J Barchi
Journal:  ACS Omega       Date:  2017-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.